Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
COMMENTARY
Will New Economic Security Bill Contribute to Ensuring Stable Drug Supplies?
The Japanese government is drafting an economic security bill it intends to submit to the Diet in late February. The draft bill aims to promote efforts to enhance supply chains for resources essential to people’s lives such as drugs, with…
To read the full story
Related Article
- MHLW Details Plan to Ensure Stable Supplies of β-Lactam Antibiotics
January 24, 2023
- Japan Designates Antibiotics as Key Resources for Economic Security
December 21, 2022
- Govt to Designate 4 β-Lactam Antibiotics as Key Resources by Year-End
November 18, 2022
- Govt Plans to Designate Key Resources Before End of Year: Minister
October 4, 2022
- Govt’s Economic Security Panel Discusses Plan for Supply Chain Survey
September 16, 2022
- Supply Chain Clause of Economic Security Law Now in Effect
August 2, 2022
- Guidelines for Securing Key Resources Endorsed by LDP, Up for Cabinet Approval
July 20, 2022
- All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Japan Enacts Economic Security Law; Supply Chain Clauses to Take Effect in 9 Months after Promulgation
May 12, 2022
- Lower House OKs Economic Security Bill
April 8, 2022
- PM Vows Effective Supply Chain Surveys as Economic Security Bill Enters Diet
March 18, 2022
- Economic Security Bill to Enter Diet Deliberations on March 17
March 17, 2022
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Cabinet OKs Draft Economic Security Bill
February 28, 2022
- Key Resource Suppliers to Be Fined for False Reporting: Draft Economic Security Bill
February 17, 2022
- Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
COMMENTARY
- How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
- Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
- Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
- Companies Welcome Generic Drug Fund, but Fret Pricing and Regulations
February 5, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…